[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f5ZJbfB69wN4z0TLbqL_DOlaytlH565enPHEMg8yKKd8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":83,"rows":90},"Centre Hospitalier Universitaire Vaudois",[4],202,false,37,5,13360162,24,139,[14,16,18,21,23,25,27,30],{"name":15,"count":9},"Postoperative Pain",{"name":17,"count":9},"Analgesia",{"name":19,"count":20},"Posttraumatic Stress Disorder",4,{"name":22,"count":20},"Melanoma",{"name":24,"count":20},"Obstructive Sleep Apnea",{"name":26,"count":20},"End Stage Renal Disease",{"name":28,"count":29},"Ischemic Stroke",3,{"name":31,"count":29},"Inflammation",[33,38,43,48,53,58,63,68,73,78],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT04807192","CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)","2025-12","CMP-001",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06293677","Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance","2026-03","Dosage Adjustment Rules for Augmented Renal Clearance (DAR-ARC) for piperacillin-tazobactam and meropenem",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05869591","DOAC in Patients with Child a or B Liver Cirrhosis","2026-06","Apixaban 5 MG [Eliquis]",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05726786","The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)","2026-08","Immunonutrition",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT07518485","Prospective Clinical Study to Identify Secondary Sentinel Lymph Nodes in Patients With N1\u002FN2b Oral Cavity or H&N Skin Cancers Using Patent Blue V and Indocyanine Green Dyes","2027-03","Patent blue V dye",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05195619","Personalized DC Vaccines in Non Small Cell Lung Cancer","2027-06","Autologous dendritic cell vaccine loaded with personalized peptides",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT07109388","Comparison of Pericapsular Nerve Group (PENG) Block With a Combined Femoral, Sciatic, Lateral Femoral Cutaneous Nerve Block for Postoperative Analgesia in Secondary Total Hip Arthroplasty; (REVPET)","2027-09-01","Pericapsular nerve group (PENG) block with 0.75% ropivacaine guided by ultrasound",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT04643574","NeoTIL in Advanced Solid Tumors","2027-11","NeoTIL",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06168175","Feasibility of Conducting a Clinical Trial Assessing Efficacy of Lactate as Adjunctive Therapy in Patients With Major Depressive Disorder","2028-01","Sodium lactate",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT07263438","Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial","2028-03-30","Trimipramine",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,116,134,162,207,230,248,266,284,302,324,345,363,387,405,438,469,516,542,568,596,614,632,656,674,700,718,746,764,782,800,818,843,861,886,904,931,958,976,994,1021,1046,1064,1089,1107,1132,1156,1182,1209,1227,1252,1270,1298,1323,1345,1372,1390,1408,1432,1450,1468,1486,1511,1529,1547,1573,1591,1616,1641,1659,1685,1703,1721,1739,1764,1782,1800,1831,1849,1867,1885,1903,1921,1939,1963,1989,2013,2038,2056,2081,2106,2124,2142,2170,2188,2206,2224,2242,2260,2283,2308,2326,2352,2370,2388,2416,2434,2452,2470,2496,2514,2532,2550,2568,2597,2615,2633,2661,2679,2697,2715,2733,2759,2777,2801,2828,2855,2873,2897,2923,2947,2974],{"intervention":42,"totalTrials":92,"cells":93},1,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":114},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":96},[],{"trials":104,"activeCount":92,"soonestReadout":41},[105],{"nctId":39,"briefTitle":40,"status":106,"phases":107,"primaryCompletion":41,"completion":41,"start":108,"enrollment":109,"conditions":110,"interventions":112},"RECRUITING",[88],"2024-03-01",30,[111],"Febrile Neutropenia",[42,113],"Standard dosages of piperacillin-tazobactam or meropenem",{"trials":115,"activeCount":96},[],{"intervention":113,"totalTrials":92,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":132},{"trials":119,"activeCount":96},[],{"trials":121,"activeCount":96},[],{"trials":123,"activeCount":96},[],{"trials":125,"activeCount":96},[],{"trials":127,"activeCount":92,"soonestReadout":41},[128],{"nctId":39,"briefTitle":40,"status":106,"phases":129,"primaryCompletion":41,"completion":41,"start":108,"enrollment":109,"conditions":130,"interventions":131},[88],[111],[42,113],{"trials":133,"activeCount":96},[],{"intervention":52,"totalTrials":92,"cells":135},{"EARLY_PHASE1":136,"PHASE1":138,"PHASE2":140,"PHASE3":142,"PHASE4":158,"NA":160},{"trials":137,"activeCount":96},[],{"trials":139,"activeCount":96},[],{"trials":141,"activeCount":96},[],{"trials":143,"activeCount":92,"soonestReadout":51},[144],{"nctId":49,"briefTitle":50,"status":106,"phases":145,"primaryCompletion":51,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":157},[87],"2026-10","2023-04-10",232,[150,151,152,153,154,155,156],"Bladder Cancer","Interstitial Cystitis","Painful Bladder Syndrome","Neurogenic Bladder","Hemorrhagic Cystitis","Endometriosis","Bladder Disease",[52],{"trials":159,"activeCount":96},[],{"trials":161,"activeCount":96},[],{"intervention":163,"totalTrials":164,"cells":165},"Bevacizumab",2,{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":201,"PHASE4":203,"NA":205},{"trials":167,"activeCount":96},[],{"trials":169,"activeCount":96},[],{"trials":171,"activeCount":92,"soonestReadout":81},[172,184],{"nctId":79,"briefTitle":80,"status":106,"phases":173,"primaryCompletion":81,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":180},[86],"2030-12-31","2025-11-03",59,[178,179],"Glioblastoma","Recurrence Tumor",[82,181,163,182,183],"Cohort 1: Atezolizumab","Cohort 2: Atezolizumab","Cohort 2: Bevacizumab",{"nctId":185,"briefTitle":186,"status":187,"phases":188,"start":189,"enrollment":190,"conditions":191,"interventions":194},"NCT00513266","Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery","UNKNOWN",[86],"2007-06",35,[192,193],"Colorectal Cancer","Metastatic Cancer",[195,196,197,198,199,200],"bevacizumab","cetuximab","fluorouracil","irinotecan hydrochloride","leucovorin calcium","oxaliplatin",{"trials":202,"activeCount":96},[],{"trials":204,"activeCount":96},[],{"trials":206,"activeCount":96},[],{"intervention":37,"totalTrials":92,"cells":208},{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":224,"PHASE4":226,"NA":228},{"trials":210,"activeCount":96},[],{"trials":212,"activeCount":96},[],{"trials":214,"activeCount":92,"soonestReadout":36},[215],{"nctId":34,"briefTitle":35,"status":216,"phases":217,"primaryCompletion":36,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},"ACTIVE_NOT_RECRUITING",[86],"2027-12","2021-04-07",40,[222],"Triple Negative Breast Cancer",[37],{"trials":225,"activeCount":96},[],{"trials":227,"activeCount":96},[],{"trials":229,"activeCount":96},[],{"intervention":82,"totalTrials":92,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":242,"PHASE4":244,"NA":246},{"trials":233,"activeCount":96},[],{"trials":235,"activeCount":96},[],{"trials":237,"activeCount":92,"soonestReadout":81},[238],{"nctId":79,"briefTitle":80,"status":106,"phases":239,"primaryCompletion":81,"completion":174,"start":175,"enrollment":176,"conditions":240,"interventions":241},[86],[178,179],[82,181,163,182,183],{"trials":243,"activeCount":96},[],{"trials":245,"activeCount":96},[],{"trials":247,"activeCount":96},[],{"intervention":181,"totalTrials":92,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":260,"PHASE4":262,"NA":264},{"trials":251,"activeCount":96},[],{"trials":253,"activeCount":96},[],{"trials":255,"activeCount":92,"soonestReadout":81},[256],{"nctId":79,"briefTitle":80,"status":106,"phases":257,"primaryCompletion":81,"completion":174,"start":175,"enrollment":176,"conditions":258,"interventions":259},[86],[178,179],[82,181,163,182,183],{"trials":261,"activeCount":96},[],{"trials":263,"activeCount":96},[],{"trials":265,"activeCount":96},[],{"intervention":182,"totalTrials":92,"cells":267},{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":278,"PHASE4":280,"NA":282},{"trials":269,"activeCount":96},[],{"trials":271,"activeCount":96},[],{"trials":273,"activeCount":92,"soonestReadout":81},[274],{"nctId":79,"briefTitle":80,"status":106,"phases":275,"primaryCompletion":81,"completion":174,"start":175,"enrollment":176,"conditions":276,"interventions":277},[86],[178,179],[82,181,163,182,183],{"trials":279,"activeCount":96},[],{"trials":281,"activeCount":96},[],{"trials":283,"activeCount":96},[],{"intervention":183,"totalTrials":92,"cells":285},{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":296,"PHASE4":298,"NA":300},{"trials":287,"activeCount":96},[],{"trials":289,"activeCount":96},[],{"trials":291,"activeCount":92,"soonestReadout":81},[292],{"nctId":79,"briefTitle":80,"status":106,"phases":293,"primaryCompletion":81,"completion":174,"start":175,"enrollment":176,"conditions":294,"interventions":295},[86],[178,179],[82,181,163,182,183],{"trials":297,"activeCount":96},[],{"trials":299,"activeCount":96},[],{"trials":301,"activeCount":96},[],{"intervention":77,"totalTrials":92,"cells":303},{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":318,"PHASE4":320,"NA":322},{"trials":305,"activeCount":96},[],{"trials":307,"activeCount":96},[],{"trials":309,"activeCount":92,"soonestReadout":76},[310],{"nctId":74,"briefTitle":75,"status":311,"phases":312,"primaryCompletion":76,"completion":76,"start":313,"enrollment":314,"conditions":315,"interventions":317},"NOT_YET_RECRUITING",[86],"2024-01",46,[316],"Major Depressive Disorder",[77],{"trials":319,"activeCount":96},[],{"trials":321,"activeCount":96},[],{"trials":323,"activeCount":96},[],{"intervention":47,"totalTrials":92,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":339,"PHASE4":341,"NA":343},{"trials":327,"activeCount":96},[],{"trials":329,"activeCount":96},[],{"trials":331,"activeCount":92,"soonestReadout":46},[332],{"nctId":44,"briefTitle":45,"status":106,"phases":333,"primaryCompletion":46,"completion":46,"start":334,"enrollment":220,"conditions":335,"interventions":337},[86],"2024-01-18",[336],"Liver Cirrhosis",[47,338],"Edoxaban 60 MG [Lixiana]",{"trials":340,"activeCount":96},[],{"trials":342,"activeCount":96},[],{"trials":344,"activeCount":96},[],{"intervention":338,"totalTrials":92,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":348,"activeCount":96},[],{"trials":350,"activeCount":96},[],{"trials":352,"activeCount":92,"soonestReadout":46},[353],{"nctId":44,"briefTitle":45,"status":106,"phases":354,"primaryCompletion":46,"completion":46,"start":334,"enrollment":220,"conditions":355,"interventions":356},[86],[336],[47,338],{"trials":358,"activeCount":96},[],{"trials":360,"activeCount":96},[],{"trials":362,"activeCount":96},[],{"intervention":57,"totalTrials":92,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":381,"PHASE4":383,"NA":385},{"trials":366,"activeCount":96},[],{"trials":368,"activeCount":96},[],{"trials":370,"activeCount":92,"soonestReadout":56},[371],{"nctId":54,"briefTitle":55,"status":311,"phases":372,"primaryCompletion":56,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":379},[86],"2027-04","2026-04",20,[377,378],"N1\u002FN2b Oral Cavity Cancer","Head and Neck Skin Cancer",[57,380],"Indocyanine green dye",{"trials":382,"activeCount":96},[],{"trials":384,"activeCount":96},[],{"trials":386,"activeCount":96},[],{"intervention":380,"totalTrials":92,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":399,"PHASE4":401,"NA":403},{"trials":390,"activeCount":96},[],{"trials":392,"activeCount":96},[],{"trials":394,"activeCount":92,"soonestReadout":56},[395],{"nctId":54,"briefTitle":55,"status":311,"phases":396,"primaryCompletion":56,"completion":373,"start":374,"enrollment":375,"conditions":397,"interventions":398},[86],[377,378],[57,380],{"trials":400,"activeCount":96},[],{"trials":402,"activeCount":96},[],{"trials":404,"activeCount":96},[],{"intervention":406,"totalTrials":164,"cells":407},"Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides",{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":409,"activeCount":96},[],{"trials":411,"activeCount":164,"soonestReadout":61},[412,422],{"nctId":413,"briefTitle":414,"status":216,"phases":415,"primaryCompletion":416,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":421},"NCT04627246","Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer",[85],"2028-09","2020-09-11",14,[420],"Pancreatic Adenocarcinoma",[406],{"nctId":59,"briefTitle":60,"status":216,"phases":423,"primaryCompletion":61,"completion":61,"start":424,"enrollment":425,"conditions":426,"interventions":428},[85],"2022-03-22",16,[427],"Non-small Cell Lung Cancer",[62,429],"Low dose cyclophosphamide",{"trials":431,"activeCount":96},[],{"trials":433,"activeCount":96},[],{"trials":435,"activeCount":96},[],{"trials":437,"activeCount":96},[],{"intervention":429,"totalTrials":164,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":448,"PHASE3":463,"PHASE4":465,"NA":467},{"trials":441,"activeCount":96},[],{"trials":443,"activeCount":92,"soonestReadout":61},[444],{"nctId":59,"briefTitle":60,"status":216,"phases":445,"primaryCompletion":61,"completion":61,"start":424,"enrollment":425,"conditions":446,"interventions":447},[85],[427],[62,429],{"trials":449,"activeCount":96},[450],{"nctId":451,"briefTitle":452,"status":453,"phases":454,"primaryCompletion":455,"completion":455,"start":456,"enrollment":96,"conditions":457,"interventions":459},"NCT05714306","PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma","WITHDRAWN",[85,86],"2030-03","2023-08-01",[458],"Ovarian Carcinoma",[460,461,462,429],"PEP-DC1","OC-DC","PEP-DC2",{"trials":464,"activeCount":96},[],{"trials":466,"activeCount":96},[],{"trials":468,"activeCount":96},[],{"intervention":470,"totalTrials":29,"cells":471},"Cyclophosphamide",{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":508,"PHASE3":510,"PHASE4":512,"NA":514},{"trials":473,"activeCount":96},[],{"trials":475,"activeCount":92,"soonestReadout":71},[476,491,502],{"nctId":477,"briefTitle":478,"status":479,"phases":480,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":485,"interventions":487},"NCT03475134","TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)","COMPLETED",[85],"2021-02-09","2024-06-06","2018-02-21",18,[486],"Metastatic Melanoma",[470,488,489,490],"Fludarabine","Interleukin-2","Nivolumab",{"nctId":492,"briefTitle":493,"status":494,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":501},"NCT03992326","Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors","TERMINATED",[85],"2021-03-05","2019-09-01",6,[500],"Solid Tumor, Adult",[470,488,489],{"nctId":69,"briefTitle":70,"status":216,"phases":503,"primaryCompletion":71,"completion":71,"start":504,"enrollment":505,"conditions":506,"interventions":507},[85],"2021-03-09",42,[500],[72,470,488,489],{"trials":509,"activeCount":96},[],{"trials":511,"activeCount":96},[],{"trials":513,"activeCount":96},[],{"trials":515,"activeCount":96},[],{"intervention":488,"totalTrials":29,"cells":517},{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":534,"PHASE3":536,"PHASE4":538,"NA":540},{"trials":519,"activeCount":96},[],{"trials":521,"activeCount":92,"soonestReadout":71},[522,526,530],{"nctId":477,"briefTitle":478,"status":479,"phases":523,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":524,"interventions":525},[85],[486],[470,488,489,490],{"nctId":492,"briefTitle":493,"status":494,"phases":527,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":528,"interventions":529},[85],[500],[470,488,489],{"nctId":69,"briefTitle":70,"status":216,"phases":531,"primaryCompletion":71,"completion":71,"start":504,"enrollment":505,"conditions":532,"interventions":533},[85],[500],[72,470,488,489],{"trials":535,"activeCount":96},[],{"trials":537,"activeCount":96},[],{"trials":539,"activeCount":96},[],{"trials":541,"activeCount":96},[],{"intervention":489,"totalTrials":29,"cells":543},{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":560,"PHASE3":562,"PHASE4":564,"NA":566},{"trials":545,"activeCount":96},[],{"trials":547,"activeCount":92,"soonestReadout":71},[548,552,556],{"nctId":477,"briefTitle":478,"status":479,"phases":549,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":550,"interventions":551},[85],[486],[470,488,489,490],{"nctId":492,"briefTitle":493,"status":494,"phases":553,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":554,"interventions":555},[85],[500],[470,488,489],{"nctId":69,"briefTitle":70,"status":216,"phases":557,"primaryCompletion":71,"completion":71,"start":504,"enrollment":505,"conditions":558,"interventions":559},[85],[500],[72,470,488,489],{"trials":561,"activeCount":96},[],{"trials":563,"activeCount":96},[],{"trials":565,"activeCount":96},[],{"trials":567,"activeCount":96},[],{"intervention":569,"totalTrials":92,"cells":570},"NY-ESO-1 TCR redirected autologous T cell product",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":588,"PHASE3":590,"PHASE4":592,"NA":594},{"trials":572,"activeCount":96},[],{"trials":574,"activeCount":92,"soonestReadout":579},[575],{"nctId":576,"briefTitle":577,"status":106,"phases":578,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":582,"interventions":586},"NCT06889766","NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma",[85],"2029-06","2025-03-24",9,[583,584,585],"Advanced Melanoma","Melanoma Metastatic","Sarcoma",[569,587],"Non-myeloablative lymphodepleting chemotherapy",{"trials":589,"activeCount":96},[],{"trials":591,"activeCount":96},[],{"trials":593,"activeCount":96},[],{"trials":595,"activeCount":96},[],{"intervention":587,"totalTrials":92,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":606,"PHASE3":608,"PHASE4":610,"NA":612},{"trials":599,"activeCount":96},[],{"trials":601,"activeCount":92,"soonestReadout":579},[602],{"nctId":576,"briefTitle":577,"status":106,"phases":603,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":604,"interventions":605},[85],[583,584,585],[569,587],{"trials":607,"activeCount":96},[],{"trials":609,"activeCount":96},[],{"trials":611,"activeCount":96},[],{"trials":613,"activeCount":96},[],{"intervention":72,"totalTrials":92,"cells":615},{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":624,"PHASE3":626,"PHASE4":628,"NA":630},{"trials":617,"activeCount":96},[],{"trials":619,"activeCount":92,"soonestReadout":71},[620],{"nctId":69,"briefTitle":70,"status":216,"phases":621,"primaryCompletion":71,"completion":71,"start":504,"enrollment":505,"conditions":622,"interventions":623},[85],[500],[72,470,488,489],{"trials":625,"activeCount":96},[],{"trials":627,"activeCount":96},[],{"trials":629,"activeCount":96},[],{"trials":631,"activeCount":96},[],{"intervention":67,"totalTrials":92,"cells":633},{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":640,"PHASE4":642,"NA":644},{"trials":635,"activeCount":96},[],{"trials":637,"activeCount":96},[],{"trials":639,"activeCount":96},[],{"trials":641,"activeCount":96},[],{"trials":643,"activeCount":96},[],{"trials":645,"activeCount":92,"soonestReadout":66},[646],{"nctId":64,"briefTitle":65,"status":311,"phases":647,"primaryCompletion":66,"completion":66,"start":648,"enrollment":649,"conditions":650,"interventions":654},[89],"2025-09-30",50,[651,652,653],"Hip Arthroplasty Replacement","Post Operative Analgesia","Post Operative Pain, Acute",[67,655],"Femoral, sciatic and lateral femoral cutaneous nerve block with 0.375% ropivacaine",{"intervention":655,"totalTrials":92,"cells":657},{"EARLY_PHASE1":658,"PHASE1":660,"PHASE2":662,"PHASE3":664,"PHASE4":666,"NA":668},{"trials":659,"activeCount":96},[],{"trials":661,"activeCount":96},[],{"trials":663,"activeCount":96},[],{"trials":665,"activeCount":96},[],{"trials":667,"activeCount":96},[],{"trials":669,"activeCount":92,"soonestReadout":66},[670],{"nctId":64,"briefTitle":65,"status":311,"phases":671,"primaryCompletion":66,"completion":66,"start":648,"enrollment":649,"conditions":672,"interventions":673},[89],[651,652,653],[67,655],{"intervention":675,"totalTrials":92,"cells":676},"Bupivacaine with normal saline",{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":683,"PHASE4":685,"NA":698},{"trials":678,"activeCount":96},[],{"trials":680,"activeCount":96},[],{"trials":682,"activeCount":96},[],{"trials":684,"activeCount":96},[],{"trials":686,"activeCount":96},[687],{"nctId":688,"briefTitle":689,"status":479,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":696},"NCT02566226","Impact of Intrathecal Morphine on Sleep Apnea Syndrome",[88],"2019-03","2015-11",60,[695],"Sleep Apnea Syndromes",[675,697],"Bupivacaine with intrathecal morphine",{"trials":699,"activeCount":96},[],{"intervention":697,"totalTrials":92,"cells":701},{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":716},{"trials":703,"activeCount":96},[],{"trials":705,"activeCount":96},[],{"trials":707,"activeCount":96},[],{"trials":709,"activeCount":96},[],{"trials":711,"activeCount":96},[712],{"nctId":688,"briefTitle":689,"status":479,"phases":713,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":714,"interventions":715},[88],[695],[675,697],{"trials":717,"activeCount":96},[],{"intervention":719,"totalTrials":92,"cells":720},"Dexamethasone 1 mg",{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":727,"PHASE4":729,"NA":744},{"trials":722,"activeCount":96},[],{"trials":724,"activeCount":96},[],{"trials":726,"activeCount":96},[],{"trials":728,"activeCount":96},[],{"trials":730,"activeCount":96},[731],{"nctId":732,"briefTitle":733,"status":479,"phases":734,"primaryCompletion":735,"completion":735,"start":736,"enrollment":737,"conditions":738,"interventions":739},"NCT02818491","Dexamethasone as an Adjuvant to Ropivacaine for the Interscalene Brachial Plexus Block",[88],"2018-11-01","2017-11-01",75,[15],[719,740,741,742,743],"Dexamethasone 2 mg","Dexamethasone 3 mg","Dexamethasone 4 mg","Ropivacaine 0.5%",{"trials":745,"activeCount":96},[],{"intervention":740,"totalTrials":92,"cells":747},{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":762},{"trials":749,"activeCount":96},[],{"trials":751,"activeCount":96},[],{"trials":753,"activeCount":96},[],{"trials":755,"activeCount":96},[],{"trials":757,"activeCount":96},[758],{"nctId":732,"briefTitle":733,"status":479,"phases":759,"primaryCompletion":735,"completion":735,"start":736,"enrollment":737,"conditions":760,"interventions":761},[88],[15],[719,740,741,742,743],{"trials":763,"activeCount":96},[],{"intervention":741,"totalTrials":92,"cells":765},{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":772,"PHASE4":774,"NA":780},{"trials":767,"activeCount":96},[],{"trials":769,"activeCount":96},[],{"trials":771,"activeCount":96},[],{"trials":773,"activeCount":96},[],{"trials":775,"activeCount":96},[776],{"nctId":732,"briefTitle":733,"status":479,"phases":777,"primaryCompletion":735,"completion":735,"start":736,"enrollment":737,"conditions":778,"interventions":779},[88],[15],[719,740,741,742,743],{"trials":781,"activeCount":96},[],{"intervention":742,"totalTrials":92,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":792,"NA":798},{"trials":785,"activeCount":96},[],{"trials":787,"activeCount":96},[],{"trials":789,"activeCount":96},[],{"trials":791,"activeCount":96},[],{"trials":793,"activeCount":96},[794],{"nctId":732,"briefTitle":733,"status":479,"phases":795,"primaryCompletion":735,"completion":735,"start":736,"enrollment":737,"conditions":796,"interventions":797},[88],[15],[719,740,741,742,743],{"trials":799,"activeCount":96},[],{"intervention":743,"totalTrials":92,"cells":801},{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":808,"PHASE4":810,"NA":816},{"trials":803,"activeCount":96},[],{"trials":805,"activeCount":96},[],{"trials":807,"activeCount":96},[],{"trials":809,"activeCount":96},[],{"trials":811,"activeCount":96},[812],{"nctId":732,"briefTitle":733,"status":479,"phases":813,"primaryCompletion":735,"completion":735,"start":736,"enrollment":737,"conditions":814,"interventions":815},[88],[15],[719,740,741,742,743],{"trials":817,"activeCount":96},[],{"intervention":819,"totalTrials":92,"cells":820},"Aliskiren",{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":829,"NA":841},{"trials":822,"activeCount":96},[],{"trials":824,"activeCount":96},[],{"trials":826,"activeCount":96},[],{"trials":828,"activeCount":96},[],{"trials":830,"activeCount":96},[831],{"nctId":832,"briefTitle":833,"status":479,"phases":834,"primaryCompletion":835,"completion":835,"start":836,"enrollment":11,"conditions":837,"interventions":839},"NCT01519635","Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension",[88],"2014-10","2011-10",[838],"Hypertension",[819,840],"Hydrochlorothiazide",{"trials":842,"activeCount":96},[],{"intervention":840,"totalTrials":92,"cells":844},{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":851,"PHASE4":853,"NA":859},{"trials":846,"activeCount":96},[],{"trials":848,"activeCount":96},[],{"trials":850,"activeCount":96},[],{"trials":852,"activeCount":96},[],{"trials":854,"activeCount":96},[855],{"nctId":832,"briefTitle":833,"status":479,"phases":856,"primaryCompletion":835,"completion":835,"start":836,"enrollment":11,"conditions":857,"interventions":858},[88],[838],[819,840],{"trials":860,"activeCount":96},[],{"intervention":862,"totalTrials":92,"cells":863},"Fentanyl and sevoflurane",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":872,"NA":884},{"trials":865,"activeCount":96},[],{"trials":867,"activeCount":96},[],{"trials":869,"activeCount":96},[],{"trials":871,"activeCount":96},[],{"trials":873,"activeCount":96},[874],{"nctId":875,"briefTitle":876,"status":479,"phases":877,"primaryCompletion":878,"completion":878,"start":879,"enrollment":693,"conditions":880,"interventions":882},"NCT02717780","Short Life Agents in Balanced Anesthesia on Obstructive Sleep Apnea Syndrome",[88],"2018-06","2016-02",[695,881],"Sleep Apnea, Obstructive",[862,883],"Remifentanil and desflurane",{"trials":885,"activeCount":96},[],{"intervention":883,"totalTrials":92,"cells":887},{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":896,"NA":902},{"trials":889,"activeCount":96},[],{"trials":891,"activeCount":96},[],{"trials":893,"activeCount":96},[],{"trials":895,"activeCount":96},[],{"trials":897,"activeCount":96},[898],{"nctId":875,"briefTitle":876,"status":479,"phases":899,"primaryCompletion":878,"completion":878,"start":879,"enrollment":693,"conditions":900,"interventions":901},[88],[695,881],[862,883],{"trials":903,"activeCount":96},[],{"intervention":905,"totalTrials":92,"cells":906},"Ropivacaine 0.5% 20 mLs",{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":915,"NA":929},{"trials":908,"activeCount":96},[],{"trials":910,"activeCount":96},[],{"trials":912,"activeCount":96},[],{"trials":914,"activeCount":96},[],{"trials":916,"activeCount":96},[917],{"nctId":918,"briefTitle":919,"status":479,"phases":920,"primaryCompletion":921,"completion":921,"start":922,"enrollment":923,"conditions":924,"interventions":928},"NCT02524652","Local Infiltration Analgesia vs Adductor Canal Block for Analgesia After Anterior Cruciate Ligament Reconstruction",[88],"2018-03","2015-09",104,[925,926,927],"Rupture of Anterior Cruciate Ligament","Infiltration","Regional Anesthesia Morbidity",[905],{"trials":930,"activeCount":96},[],{"intervention":932,"totalTrials":92,"cells":933},"Dexamethasone",{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":942,"NA":956},{"trials":935,"activeCount":96},[],{"trials":937,"activeCount":96},[],{"trials":939,"activeCount":96},[],{"trials":941,"activeCount":96},[],{"trials":943,"activeCount":96},[944],{"nctId":945,"briefTitle":946,"status":479,"phases":947,"primaryCompletion":948,"completion":948,"start":949,"enrollment":950,"conditions":951,"interventions":953},"NCT01434017","Comparison of Three Different Prophylactic Treatments of Postoperative Nausea and Vomiting (PONV) in Children",[88],"2013-06","2008-11",300,[952],"Postoperative Nausea and Vomiting",[932,954,955],"Dexamethasone and droperidol","Dexamethasone and Ondansetron",{"trials":957,"activeCount":96},[],{"intervention":954,"totalTrials":92,"cells":959},{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":966,"PHASE4":968,"NA":974},{"trials":961,"activeCount":96},[],{"trials":963,"activeCount":96},[],{"trials":965,"activeCount":96},[],{"trials":967,"activeCount":96},[],{"trials":969,"activeCount":96},[970],{"nctId":945,"briefTitle":946,"status":479,"phases":971,"primaryCompletion":948,"completion":948,"start":949,"enrollment":950,"conditions":972,"interventions":973},[88],[952],[932,954,955],{"trials":975,"activeCount":96},[],{"intervention":955,"totalTrials":92,"cells":977},{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":992},{"trials":979,"activeCount":96},[],{"trials":981,"activeCount":96},[],{"trials":983,"activeCount":96},[],{"trials":985,"activeCount":96},[],{"trials":987,"activeCount":96},[988],{"nctId":945,"briefTitle":946,"status":479,"phases":989,"primaryCompletion":948,"completion":948,"start":949,"enrollment":950,"conditions":990,"interventions":991},[88],[952],[932,954,955],{"trials":993,"activeCount":96},[],{"intervention":995,"totalTrials":92,"cells":996},"SSRI\u002FSNRI",{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1003,"PHASE4":1005,"NA":1019},{"trials":998,"activeCount":96},[],{"trials":1000,"activeCount":96},[],{"trials":1002,"activeCount":96},[],{"trials":1004,"activeCount":96},[],{"trials":1006,"activeCount":96},[1007],{"nctId":1008,"briefTitle":1009,"status":187,"phases":1010,"primaryCompletion":1011,"completion":1012,"start":1013,"enrollment":1014,"conditions":1015,"interventions":1018},"NCT01796132","Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications",[88],"2016-12","2018-12","2012-08",500,[1016,1017],"Depressive Disorder","Lactation",[995],{"trials":1020,"activeCount":96},[],{"intervention":1022,"totalTrials":92,"cells":1023},"Normal saline",{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1030,"PHASE4":1032,"NA":1044},{"trials":1025,"activeCount":96},[],{"trials":1027,"activeCount":96},[],{"trials":1029,"activeCount":96},[],{"trials":1031,"activeCount":96},[],{"trials":1033,"activeCount":96},[1034],{"nctId":1035,"briefTitle":1036,"status":453,"phases":1037,"primaryCompletion":1038,"completion":1038,"start":1039,"enrollment":96,"conditions":1040,"interventions":1042},"NCT02562417","Impact of iv Dexamethasone on Reversal of Rocuronium-induced Neuromuscular Block by Sugammadex",[88],"2018-05","2016-06",[1041],"Neuromuscular Blockade",[1022,1043],"IV dexamethasone",{"trials":1045,"activeCount":96},[],{"intervention":1043,"totalTrials":92,"cells":1047},{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1054,"PHASE4":1056,"NA":1062},{"trials":1049,"activeCount":96},[],{"trials":1051,"activeCount":96},[],{"trials":1053,"activeCount":96},[],{"trials":1055,"activeCount":96},[],{"trials":1057,"activeCount":96},[1058],{"nctId":1035,"briefTitle":1036,"status":453,"phases":1059,"primaryCompletion":1038,"completion":1038,"start":1039,"enrollment":96,"conditions":1060,"interventions":1061},[88],[1041],[1022,1043],{"trials":1063,"activeCount":96},[],{"intervention":1065,"totalTrials":92,"cells":1066},"Oxycodone",{"EARLY_PHASE1":1067,"PHASE1":1069,"PHASE2":1071,"PHASE3":1073,"PHASE4":1075,"NA":1087},{"trials":1068,"activeCount":96},[],{"trials":1070,"activeCount":96},[],{"trials":1072,"activeCount":96},[],{"trials":1074,"activeCount":96},[],{"trials":1076,"activeCount":96},[1077],{"nctId":1078,"briefTitle":1079,"status":479,"phases":1080,"primaryCompletion":1081,"completion":1081,"start":1082,"enrollment":693,"conditions":1083,"interventions":1085},"NCT03454217","Impact of Tramadol and Oxycodone on Sleep Apnea",[88],"2020-09-30","2018-03-01",[1084],"Sleep Apnea",[1065,1086],"Tramadol",{"trials":1088,"activeCount":96},[],{"intervention":1086,"totalTrials":92,"cells":1090},{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1095,"PHASE3":1097,"PHASE4":1099,"NA":1105},{"trials":1092,"activeCount":96},[],{"trials":1094,"activeCount":96},[],{"trials":1096,"activeCount":96},[],{"trials":1098,"activeCount":96},[],{"trials":1100,"activeCount":96},[1101],{"nctId":1078,"briefTitle":1079,"status":479,"phases":1102,"primaryCompletion":1081,"completion":1081,"start":1082,"enrollment":693,"conditions":1103,"interventions":1104},[88],[1084],[1065,1086],{"trials":1106,"activeCount":96},[],{"intervention":1108,"totalTrials":92,"cells":1109},"cefuroxime",{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1114,"PHASE3":1116,"PHASE4":1118,"NA":1130},{"trials":1111,"activeCount":96},[],{"trials":1113,"activeCount":96},[],{"trials":1115,"activeCount":96},[],{"trials":1117,"activeCount":96},[],{"trials":1119,"activeCount":96},[1120],{"nctId":1121,"briefTitle":1122,"status":479,"phases":1123,"completion":1124,"start":1125,"enrollment":1126,"conditions":1127,"interventions":1129},"NCT00530400","Study of the Efficacy of Preoperative Cefuroxime Prophylaxis to Prevent Surgical Site Infection in Herniated Disk Surgery",[88],"2000-03","1994-04",1369,[1128],"Surgical Wound Infection",[1108],{"trials":1131,"activeCount":96},[],{"intervention":1133,"totalTrials":92,"cells":1134},"Pioglitazone",{"EARLY_PHASE1":1135,"PHASE1":1137,"PHASE2":1139,"PHASE3":1141,"PHASE4":1143,"NA":1154},{"trials":1136,"activeCount":96},[],{"trials":1138,"activeCount":96},[],{"trials":1140,"activeCount":96},[],{"trials":1142,"activeCount":96},[],{"trials":1144,"activeCount":96},[1145],{"nctId":1146,"briefTitle":1147,"status":187,"phases":1148,"primaryCompletion":1149,"start":1150,"enrollment":425,"conditions":1151,"interventions":1153},"NCT01253928","Pioglitazone, Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD",[88],"2011-06","2007-03",[1152],"ESRD",[1133],{"trials":1155,"activeCount":96},[],{"intervention":1157,"totalTrials":92,"cells":1158},"tamoxifen citrate",{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1165,"PHASE4":1178,"NA":1180},{"trials":1160,"activeCount":96},[],{"trials":1162,"activeCount":96},[],{"trials":1164,"activeCount":96},[],{"trials":1166,"activeCount":96},[1167],{"nctId":1168,"briefTitle":1169,"status":187,"phases":1170,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":1174,"conditions":1175,"interventions":1177},"NCT00963209","Tamoxifen Citrate in Patients With Breast Cancer",[87],"2013-09","2013-12","2009-06",140,[1176],"Breast Cancer",[1157],{"trials":1179,"activeCount":96},[],{"trials":1181,"activeCount":96},[],{"intervention":1183,"totalTrials":92,"cells":1184},"Fish oil emulsion",{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1191,"PHASE4":1205,"NA":1207},{"trials":1186,"activeCount":96},[],{"trials":1188,"activeCount":96},[],{"trials":1190,"activeCount":96},[],{"trials":1192,"activeCount":96},[1193],{"nctId":1194,"briefTitle":1195,"status":479,"phases":1196,"primaryCompletion":1197,"completion":1198,"start":1199,"enrollment":1200,"conditions":1201,"interventions":1203},"NCT00516178","Intravenous Fish Oil in Critically Ill Cardiac Patients",[87],"2011-03","2011-04","2008-01",31,[1202],"Coronary Artery Disease",[1183,1204],"Saline",{"trials":1206,"activeCount":96},[],{"trials":1208,"activeCount":96},[],{"intervention":1204,"totalTrials":92,"cells":1210},{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1217,"PHASE4":1223,"NA":1225},{"trials":1212,"activeCount":96},[],{"trials":1214,"activeCount":96},[],{"trials":1216,"activeCount":96},[],{"trials":1218,"activeCount":96},[1219],{"nctId":1194,"briefTitle":1195,"status":479,"phases":1220,"primaryCompletion":1197,"completion":1198,"start":1199,"enrollment":1200,"conditions":1221,"interventions":1222},[87],[1202],[1183,1204],{"trials":1224,"activeCount":96},[],{"trials":1226,"activeCount":96},[],{"intervention":1228,"totalTrials":92,"cells":1229},"Glucose-Insulin-Potassium",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1236,"PHASE4":1248,"NA":1250},{"trials":1231,"activeCount":96},[],{"trials":1233,"activeCount":96},[],{"trials":1235,"activeCount":96},[],{"trials":1237,"activeCount":96},[1238],{"nctId":1239,"briefTitle":1240,"status":187,"phases":1241,"primaryCompletion":1242,"start":879,"enrollment":1243,"conditions":1244,"interventions":1246},"NCT02591927","Reappraisal of GIK in Acute STEMI by Pre-hospital Administration",[87],"2019-02",334,[1245],"Myocardial Infarction",[1228,1247],"Glucose 5%",{"trials":1249,"activeCount":96},[],{"trials":1251,"activeCount":96},[],{"intervention":1247,"totalTrials":92,"cells":1253},{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1258,"PHASE3":1260,"PHASE4":1266,"NA":1268},{"trials":1255,"activeCount":96},[],{"trials":1257,"activeCount":96},[],{"trials":1259,"activeCount":96},[],{"trials":1261,"activeCount":96},[1262],{"nctId":1239,"briefTitle":1240,"status":187,"phases":1263,"primaryCompletion":1242,"start":879,"enrollment":1243,"conditions":1264,"interventions":1265},[87],[1245],[1228,1247],{"trials":1267,"activeCount":96},[],{"trials":1269,"activeCount":96},[],{"intervention":1271,"totalTrials":92,"cells":1272},"Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E",{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1294,"NA":1296},{"trials":1274,"activeCount":96},[],{"trials":1276,"activeCount":96},[],{"trials":1278,"activeCount":96},[],{"trials":1280,"activeCount":96},[1281],{"nctId":1282,"briefTitle":1283,"status":494,"phases":1284,"primaryCompletion":1285,"completion":1285,"start":1286,"enrollment":1287,"conditions":1288,"interventions":1293},"NCT00515736","Impact Of Antioxidant Micronutrients On Intensive Care Unit (ICU) Outcome",[87],"2005-12","2003-01",200,[1289,1290,1291,1292],"Critically Ill Patients","Cardiac Surgery","Trauma","Subarachnoid Hemorrhage",[1271],{"trials":1295,"activeCount":96},[],{"trials":1297,"activeCount":96},[],{"intervention":196,"totalTrials":164,"cells":1299},{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1311,"PHASE3":1317,"PHASE4":1319,"NA":1321},{"trials":1301,"activeCount":96},[],{"trials":1303,"activeCount":96},[1304],{"nctId":1305,"briefTitle":1306,"status":187,"phases":1307,"start":1308,"enrollment":375,"conditions":1309,"interventions":1310},"NCT00392470","Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer",[85],"2006-08",[192],[196,198],{"trials":1312,"activeCount":96},[1313],{"nctId":185,"briefTitle":186,"status":187,"phases":1314,"start":189,"enrollment":190,"conditions":1315,"interventions":1316},[86],[192,193],[195,196,197,198,199,200],{"trials":1318,"activeCount":96},[],{"trials":1320,"activeCount":96},[],{"trials":1322,"activeCount":96},[],{"intervention":198,"totalTrials":164,"cells":1324},{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1333,"PHASE3":1339,"PHASE4":1341,"NA":1343},{"trials":1326,"activeCount":96},[],{"trials":1328,"activeCount":96},[1329],{"nctId":1305,"briefTitle":1306,"status":187,"phases":1330,"start":1308,"enrollment":375,"conditions":1331,"interventions":1332},[85],[192],[196,198],{"trials":1334,"activeCount":96},[1335],{"nctId":185,"briefTitle":186,"status":187,"phases":1336,"start":189,"enrollment":190,"conditions":1337,"interventions":1338},[86],[192,193],[195,196,197,198,199,200],{"trials":1340,"activeCount":96},[],{"trials":1342,"activeCount":96},[],{"trials":1344,"activeCount":96},[],{"intervention":1346,"totalTrials":92,"cells":1347},"PANITUMUMAB",{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1366,"PHASE4":1368,"NA":1370},{"trials":1349,"activeCount":96},[],{"trials":1351,"activeCount":96},[],{"trials":1353,"activeCount":96},[1354],{"nctId":1355,"briefTitle":1356,"status":494,"phases":1357,"primaryCompletion":1358,"completion":1358,"start":1359,"enrollment":1360,"conditions":1361,"interventions":1363},"NCT01843452","Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal",[86],"2016-05","2012-12",8,[1362],"Carcinoma of Anal Canal",[1346,1364,1365],"MITOMYCIN","CAPECITABINE",{"trials":1367,"activeCount":96},[],{"trials":1369,"activeCount":96},[],{"trials":1371,"activeCount":96},[],{"intervention":1364,"totalTrials":92,"cells":1373},{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1378,"PHASE3":1384,"PHASE4":1386,"NA":1388},{"trials":1375,"activeCount":96},[],{"trials":1377,"activeCount":96},[],{"trials":1379,"activeCount":96},[1380],{"nctId":1355,"briefTitle":1356,"status":494,"phases":1381,"primaryCompletion":1358,"completion":1358,"start":1359,"enrollment":1360,"conditions":1382,"interventions":1383},[86],[1362],[1346,1364,1365],{"trials":1385,"activeCount":96},[],{"trials":1387,"activeCount":96},[],{"trials":1389,"activeCount":96},[],{"intervention":1365,"totalTrials":92,"cells":1391},{"EARLY_PHASE1":1392,"PHASE1":1394,"PHASE2":1396,"PHASE3":1402,"PHASE4":1404,"NA":1406},{"trials":1393,"activeCount":96},[],{"trials":1395,"activeCount":96},[],{"trials":1397,"activeCount":96},[1398],{"nctId":1355,"briefTitle":1356,"status":494,"phases":1399,"primaryCompletion":1358,"completion":1358,"start":1359,"enrollment":1360,"conditions":1400,"interventions":1401},[86],[1362],[1346,1364,1365],{"trials":1403,"activeCount":96},[],{"trials":1405,"activeCount":96},[],{"trials":1407,"activeCount":96},[],{"intervention":1409,"totalTrials":92,"cells":1410},"cAd3-EBOZ vaccine",{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1426,"PHASE4":1428,"NA":1430},{"trials":1412,"activeCount":96},[],{"trials":1414,"activeCount":96},[],{"trials":1416,"activeCount":96},[1417],{"nctId":1418,"briefTitle":1419,"status":479,"phases":1420,"primaryCompletion":1421,"completion":1421,"start":835,"enrollment":1422,"conditions":1423,"interventions":1425},"NCT02289027","A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland",[85,86],"2015-06",120,[1424],"Ebola Vaccines",[1409],{"trials":1427,"activeCount":96},[],{"trials":1429,"activeCount":96},[],{"trials":1431,"activeCount":96},[],{"intervention":197,"totalTrials":92,"cells":1433},{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1444,"PHASE4":1446,"NA":1448},{"trials":1435,"activeCount":96},[],{"trials":1437,"activeCount":96},[],{"trials":1439,"activeCount":96},[1440],{"nctId":185,"briefTitle":186,"status":187,"phases":1441,"start":189,"enrollment":190,"conditions":1442,"interventions":1443},[86],[192,193],[195,196,197,198,199,200],{"trials":1445,"activeCount":96},[],{"trials":1447,"activeCount":96},[],{"trials":1449,"activeCount":96},[],{"intervention":199,"totalTrials":92,"cells":1451},{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1462,"PHASE4":1464,"NA":1466},{"trials":1453,"activeCount":96},[],{"trials":1455,"activeCount":96},[],{"trials":1457,"activeCount":96},[1458],{"nctId":185,"briefTitle":186,"status":187,"phases":1459,"start":189,"enrollment":190,"conditions":1460,"interventions":1461},[86],[192,193],[195,196,197,198,199,200],{"trials":1463,"activeCount":96},[],{"trials":1465,"activeCount":96},[],{"trials":1467,"activeCount":96},[],{"intervention":200,"totalTrials":92,"cells":1469},{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1480,"PHASE4":1482,"NA":1484},{"trials":1471,"activeCount":96},[],{"trials":1473,"activeCount":96},[],{"trials":1475,"activeCount":96},[1476],{"nctId":185,"briefTitle":186,"status":187,"phases":1477,"start":189,"enrollment":190,"conditions":1478,"interventions":1479},[86],[192,193],[195,196,197,198,199,200],{"trials":1481,"activeCount":96},[],{"trials":1483,"activeCount":96},[],{"trials":1485,"activeCount":96},[],{"intervention":1487,"totalTrials":92,"cells":1488},"celecoxib",{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1505,"PHASE4":1507,"NA":1509},{"trials":1490,"activeCount":96},[],{"trials":1492,"activeCount":96},[],{"trials":1494,"activeCount":96},[1495],{"nctId":1496,"briefTitle":1497,"status":187,"phases":1498,"start":1499,"enrollment":11,"conditions":1500,"interventions":1502},"NCT00357617","Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery",[85,86],"2006-06",[1501],"Head and Neck Cancer",[1487,1503,1504],"microarray analysis","protein expression analysis",{"trials":1506,"activeCount":96},[],{"trials":1508,"activeCount":96},[],{"trials":1510,"activeCount":96},[],{"intervention":1503,"totalTrials":92,"cells":1512},{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1523,"PHASE4":1525,"NA":1527},{"trials":1514,"activeCount":96},[],{"trials":1516,"activeCount":96},[],{"trials":1518,"activeCount":96},[1519],{"nctId":1496,"briefTitle":1497,"status":187,"phases":1520,"start":1499,"enrollment":11,"conditions":1521,"interventions":1522},[85,86],[1501],[1487,1503,1504],{"trials":1524,"activeCount":96},[],{"trials":1526,"activeCount":96},[],{"trials":1528,"activeCount":96},[],{"intervention":1504,"totalTrials":92,"cells":1530},{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1541,"PHASE4":1543,"NA":1545},{"trials":1532,"activeCount":96},[],{"trials":1534,"activeCount":96},[],{"trials":1536,"activeCount":96},[1537],{"nctId":1496,"briefTitle":1497,"status":187,"phases":1538,"start":1499,"enrollment":11,"conditions":1539,"interventions":1540},[85,86],[1501],[1487,1503,1504],{"trials":1542,"activeCount":96},[],{"trials":1544,"activeCount":96},[],{"trials":1546,"activeCount":96},[],{"intervention":1548,"totalTrials":92,"cells":1549},"Dapagliflozin",{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1551,"activeCount":96},[],{"trials":1553,"activeCount":96},[],{"trials":1555,"activeCount":96},[1556],{"nctId":1557,"briefTitle":1558,"status":187,"phases":1559,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":1562,"conditions":1563,"interventions":1565},"NCT06012266","Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale",[86],"2025-08","2024-08",12,[1564],"Heart Failure",[1548,1566],"Empagliflozin",{"trials":1568,"activeCount":96},[],{"trials":1570,"activeCount":96},[],{"trials":1572,"activeCount":96},[],{"intervention":1566,"totalTrials":92,"cells":1574},{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1585,"PHASE4":1587,"NA":1589},{"trials":1576,"activeCount":96},[],{"trials":1578,"activeCount":96},[],{"trials":1580,"activeCount":96},[1581],{"nctId":1557,"briefTitle":1558,"status":187,"phases":1582,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":1562,"conditions":1583,"interventions":1584},[86],[1564],[1548,1566],{"trials":1586,"activeCount":96},[],{"trials":1588,"activeCount":96},[],{"trials":1590,"activeCount":96},[],{"intervention":1592,"totalTrials":92,"cells":1593},"Lactate",{"EARLY_PHASE1":1594,"PHASE1":1596,"PHASE2":1598,"PHASE3":1610,"PHASE4":1612,"NA":1614},{"trials":1595,"activeCount":96},[],{"trials":1597,"activeCount":96},[],{"trials":1599,"activeCount":96},[1600],{"nctId":1601,"briefTitle":1602,"status":494,"phases":1603,"primaryCompletion":1604,"completion":1604,"start":1605,"enrollment":1606,"conditions":1607,"interventions":1609},"NCT04858139","Exploring the Effect of Lactate Administration After Ischemic Stroke on Brain Metabolism",[86],"2025-03-27","2021-08-05",28,[1608],"Stroke, Acute",[1592],{"trials":1611,"activeCount":96},[],{"trials":1613,"activeCount":96},[],{"trials":1615,"activeCount":96},[],{"intervention":1617,"totalTrials":92,"cells":1618},"Pembrolizumab",{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1623,"PHASE3":1635,"PHASE4":1637,"NA":1639},{"trials":1620,"activeCount":96},[],{"trials":1622,"activeCount":96},[],{"trials":1624,"activeCount":96},[1625],{"nctId":1626,"briefTitle":1627,"status":187,"phases":1628,"primaryCompletion":1629,"completion":1629,"start":1630,"enrollment":109,"conditions":1631,"interventions":1633},"NCT03534635","Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)",[86],"2026-06-01","2018-06-01",[1632],"Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting",[1617,1634],"Pembrolizumab - additional treatment",{"trials":1636,"activeCount":96},[],{"trials":1638,"activeCount":96},[],{"trials":1640,"activeCount":96},[],{"intervention":1634,"totalTrials":92,"cells":1642},{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1647,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1644,"activeCount":96},[],{"trials":1646,"activeCount":96},[],{"trials":1648,"activeCount":96},[1649],{"nctId":1626,"briefTitle":1627,"status":187,"phases":1650,"primaryCompletion":1629,"completion":1629,"start":1630,"enrollment":109,"conditions":1651,"interventions":1652},[86],[1632],[1617,1634],{"trials":1654,"activeCount":96},[],{"trials":1656,"activeCount":96},[],{"trials":1658,"activeCount":96},[],{"intervention":1660,"totalTrials":92,"cells":1661},"Empagliflozin 10 mg",{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1679,"PHASE4":1681,"NA":1683},{"trials":1663,"activeCount":96},[],{"trials":1665,"activeCount":96},[],{"trials":1667,"activeCount":96},[1668],{"nctId":1669,"briefTitle":1670,"status":479,"phases":1671,"primaryCompletion":1672,"completion":1673,"start":1674,"enrollment":1675,"conditions":1676,"interventions":1678},"NCT03093103","Empagliflozin and Renal Oxygenation in Healthy Volunteers",[86],"2018-12-30","2018-12-31","2017-03-16",45,[1677],"Nephropathy",[1660],{"trials":1680,"activeCount":96},[],{"trials":1682,"activeCount":96},[],{"trials":1684,"activeCount":96},[],{"intervention":460,"totalTrials":92,"cells":1686},{"EARLY_PHASE1":1687,"PHASE1":1689,"PHASE2":1691,"PHASE3":1697,"PHASE4":1699,"NA":1701},{"trials":1688,"activeCount":96},[],{"trials":1690,"activeCount":96},[],{"trials":1692,"activeCount":96},[1693],{"nctId":451,"briefTitle":452,"status":453,"phases":1694,"primaryCompletion":455,"completion":455,"start":456,"enrollment":96,"conditions":1695,"interventions":1696},[85,86],[458],[460,461,462,429],{"trials":1698,"activeCount":96},[],{"trials":1700,"activeCount":96},[],{"trials":1702,"activeCount":96},[],{"intervention":461,"totalTrials":92,"cells":1704},{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1715,"PHASE4":1717,"NA":1719},{"trials":1706,"activeCount":96},[],{"trials":1708,"activeCount":96},[],{"trials":1710,"activeCount":96},[1711],{"nctId":451,"briefTitle":452,"status":453,"phases":1712,"primaryCompletion":455,"completion":455,"start":456,"enrollment":96,"conditions":1713,"interventions":1714},[85,86],[458],[460,461,462,429],{"trials":1716,"activeCount":96},[],{"trials":1718,"activeCount":96},[],{"trials":1720,"activeCount":96},[],{"intervention":462,"totalTrials":92,"cells":1722},{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1727,"PHASE3":1733,"PHASE4":1735,"NA":1737},{"trials":1724,"activeCount":96},[],{"trials":1726,"activeCount":96},[],{"trials":1728,"activeCount":96},[1729],{"nctId":451,"briefTitle":452,"status":453,"phases":1730,"primaryCompletion":455,"completion":455,"start":456,"enrollment":96,"conditions":1731,"interventions":1732},[85,86],[458],[460,461,462,429],{"trials":1734,"activeCount":96},[],{"trials":1736,"activeCount":96},[],{"trials":1738,"activeCount":96},[],{"intervention":1740,"totalTrials":92,"cells":1741},"2 vaccine injections in 1 limb",{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1758,"PHASE4":1760,"NA":1762},{"trials":1743,"activeCount":96},[],{"trials":1745,"activeCount":96},[],{"trials":1747,"activeCount":96},[1748],{"nctId":1749,"briefTitle":1750,"status":494,"phases":1751,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":425,"conditions":1754,"interventions":1755},"NCT01308294","Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients",[85,86],"2014-04","2010-06",[22],[1740,1756,1757],"2 vaccine injections in distinct limbs","2 \"vaccine injections\" in distinct limbs",{"trials":1759,"activeCount":96},[],{"trials":1761,"activeCount":96},[],{"trials":1763,"activeCount":96},[],{"intervention":1756,"totalTrials":92,"cells":1765},{"EARLY_PHASE1":1766,"PHASE1":1768,"PHASE2":1770,"PHASE3":1776,"PHASE4":1778,"NA":1780},{"trials":1767,"activeCount":96},[],{"trials":1769,"activeCount":96},[],{"trials":1771,"activeCount":96},[1772],{"nctId":1749,"briefTitle":1750,"status":494,"phases":1773,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":425,"conditions":1774,"interventions":1775},[85,86],[22],[1740,1756,1757],{"trials":1777,"activeCount":96},[],{"trials":1779,"activeCount":96},[],{"trials":1781,"activeCount":96},[],{"intervention":1757,"totalTrials":92,"cells":1783},{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1794,"PHASE4":1796,"NA":1798},{"trials":1785,"activeCount":96},[],{"trials":1787,"activeCount":96},[],{"trials":1789,"activeCount":96},[1790],{"nctId":1749,"briefTitle":1750,"status":494,"phases":1791,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":425,"conditions":1792,"interventions":1793},[85,86],[22],[1740,1756,1757],{"trials":1795,"activeCount":96},[],{"trials":1797,"activeCount":96},[],{"trials":1799,"activeCount":96},[],{"intervention":1801,"totalTrials":92,"cells":1802},"CH-Alum50",{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1823,"PHASE3":1825,"PHASE4":1827,"NA":1829},{"trials":1804,"activeCount":96},[],{"trials":1806,"activeCount":96},[1807],{"nctId":1808,"briefTitle":1809,"status":479,"phases":1810,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":1813,"conditions":1814,"interventions":1816},"NCT01949909","Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia\u002FIb",[85],"2015-07","2014-03",56,[1815],"Malaria",[1801,1817,1818,1819,1820,1821,1822],"CH-GLA2.5\u002F50","TZ Ver","TZ Alum 50","TZ GLA 2.5\u002F10","TZ GLA5\u002F50","TZ GLA2.5\u002F50",{"trials":1824,"activeCount":96},[],{"trials":1826,"activeCount":96},[],{"trials":1828,"activeCount":96},[],{"trials":1830,"activeCount":96},[],{"intervention":1817,"totalTrials":92,"cells":1832},{"EARLY_PHASE1":1833,"PHASE1":1835,"PHASE2":1841,"PHASE3":1843,"PHASE4":1845,"NA":1847},{"trials":1834,"activeCount":96},[],{"trials":1836,"activeCount":96},[1837],{"nctId":1808,"briefTitle":1809,"status":479,"phases":1838,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":1813,"conditions":1839,"interventions":1840},[85],[1815],[1801,1817,1818,1819,1820,1821,1822],{"trials":1842,"activeCount":96},[],{"trials":1844,"activeCount":96},[],{"trials":1846,"activeCount":96},[],{"trials":1848,"activeCount":96},[],{"intervention":1818,"totalTrials":92,"cells":1850},{"EARLY_PHASE1":1851,"PHASE1":1853,"PHASE2":1859,"PHASE3":1861,"PHASE4":1863,"NA":1865},{"trials":1852,"activeCount":96},[],{"trials":1854,"activeCount":96},[1855],{"nctId":1808,"briefTitle":1809,"status":479,"phases":1856,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":1813,"conditions":1857,"interventions":1858},[85],[1815],[1801,1817,1818,1819,1820,1821,1822],{"trials":1860,"activeCount":96},[],{"trials":1862,"activeCount":96},[],{"trials":1864,"activeCount":96},[],{"trials":1866,"activeCount":96},[],{"intervention":1819,"totalTrials":92,"cells":1868},{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1877,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1870,"activeCount":96},[],{"trials":1872,"activeCount":96},[1873],{"nctId":1808,"briefTitle":1809,"status":479,"phases":1874,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":1813,"conditions":1875,"interventions":1876},[85],[1815],[1801,1817,1818,1819,1820,1821,1822],{"trials":1878,"activeCount":96},[],{"trials":1880,"activeCount":96},[],{"trials":1882,"activeCount":96},[],{"trials":1884,"activeCount":96},[],{"intervention":1820,"totalTrials":92,"cells":1886},{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1895,"PHASE3":1897,"PHASE4":1899,"NA":1901},{"trials":1888,"activeCount":96},[],{"trials":1890,"activeCount":96},[1891],{"nctId":1808,"briefTitle":1809,"status":479,"phases":1892,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":1813,"conditions":1893,"interventions":1894},[85],[1815],[1801,1817,1818,1819,1820,1821,1822],{"trials":1896,"activeCount":96},[],{"trials":1898,"activeCount":96},[],{"trials":1900,"activeCount":96},[],{"trials":1902,"activeCount":96},[],{"intervention":1821,"totalTrials":92,"cells":1904},{"EARLY_PHASE1":1905,"PHASE1":1907,"PHASE2":1913,"PHASE3":1915,"PHASE4":1917,"NA":1919},{"trials":1906,"activeCount":96},[],{"trials":1908,"activeCount":96},[1909],{"nctId":1808,"briefTitle":1809,"status":479,"phases":1910,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":1813,"conditions":1911,"interventions":1912},[85],[1815],[1801,1817,1818,1819,1820,1821,1822],{"trials":1914,"activeCount":96},[],{"trials":1916,"activeCount":96},[],{"trials":1918,"activeCount":96},[],{"trials":1920,"activeCount":96},[],{"intervention":1822,"totalTrials":92,"cells":1922},{"EARLY_PHASE1":1923,"PHASE1":1925,"PHASE2":1931,"PHASE3":1933,"PHASE4":1935,"NA":1937},{"trials":1924,"activeCount":96},[],{"trials":1926,"activeCount":96},[1927],{"nctId":1808,"briefTitle":1809,"status":479,"phases":1928,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":1813,"conditions":1929,"interventions":1930},[85],[1815],[1801,1817,1818,1819,1820,1821,1822],{"trials":1932,"activeCount":96},[],{"trials":1934,"activeCount":96},[],{"trials":1936,"activeCount":96},[],{"trials":1938,"activeCount":96},[],{"intervention":1940,"totalTrials":92,"cells":1941},"Sorafenib",{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1955,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1943,"activeCount":96},[],{"trials":1945,"activeCount":96},[1946],{"nctId":1947,"briefTitle":1948,"status":479,"phases":1949,"primaryCompletion":1950,"completion":1950,"start":948,"enrollment":1951,"conditions":1952,"interventions":1954},"NCT01893099","Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma",[85],"2017-11-28",11,[1953],"Ocular Melanoma",[1940],{"trials":1956,"activeCount":96},[],{"trials":1958,"activeCount":96},[],{"trials":1960,"activeCount":96},[],{"trials":1962,"activeCount":96},[],{"intervention":1964,"totalTrials":92,"cells":1965},"N-Acetyl-Cysteine",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1981,"PHASE3":1983,"PHASE4":1985,"NA":1987},{"trials":1967,"activeCount":96},[],{"trials":1969,"activeCount":96},[1970],{"nctId":1971,"briefTitle":1972,"status":479,"phases":1973,"primaryCompletion":1974,"completion":1975,"start":1976,"enrollment":1977,"conditions":1978,"interventions":1980},"NCT01506765","Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia",[85],"2004-12","2006-09","2003-08",13,[1979],"Schizophrenia",[1964],{"trials":1982,"activeCount":96},[],{"trials":1984,"activeCount":96},[],{"trials":1986,"activeCount":96},[],{"trials":1988,"activeCount":96},[],{"intervention":1990,"totalTrials":92,"cells":1991},"Interferon beta-1a",{"EARLY_PHASE1":1992,"PHASE1":1994,"PHASE2":2005,"PHASE3":2007,"PHASE4":2009,"NA":2011},{"trials":1993,"activeCount":96},[],{"trials":1995,"activeCount":96},[1996],{"nctId":1997,"briefTitle":1998,"status":479,"phases":1999,"primaryCompletion":2000,"completion":2000,"start":2001,"enrollment":1562,"conditions":2002,"interventions":2004},"NCT02515695","Phase I BP Interferon (IFN) Beta-001",[85],"2005-07","2005-05",[2003],"Multiple Sclerosis, Relapsing-Remitting",[1990],{"trials":2006,"activeCount":96},[],{"trials":2008,"activeCount":96},[],{"trials":2010,"activeCount":96},[],{"trials":2012,"activeCount":96},[],{"intervention":2014,"totalTrials":92,"cells":2015},"Cisplatin, liposomal",{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2030,"PHASE3":2032,"PHASE4":2034,"NA":2036},{"trials":2017,"activeCount":96},[],{"trials":2019,"activeCount":96},[2020],{"nctId":2021,"briefTitle":2022,"status":494,"phases":2023,"primaryCompletion":2024,"completion":2024,"start":2025,"enrollment":92,"conditions":2026,"interventions":2028},"NCT02702700","Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies",[85],"2018-08-28","2016-01",[2027],"Pleural Effusion, Malignant",[2014,2029],"Verteporfin",{"trials":2031,"activeCount":96},[],{"trials":2033,"activeCount":96},[],{"trials":2035,"activeCount":96},[],{"trials":2037,"activeCount":96},[],{"intervention":2029,"totalTrials":92,"cells":2039},{"EARLY_PHASE1":2040,"PHASE1":2042,"PHASE2":2048,"PHASE3":2050,"PHASE4":2052,"NA":2054},{"trials":2041,"activeCount":96},[],{"trials":2043,"activeCount":96},[2044],{"nctId":2021,"briefTitle":2022,"status":494,"phases":2045,"primaryCompletion":2024,"completion":2024,"start":2025,"enrollment":92,"conditions":2046,"interventions":2047},[85],[2027],[2014,2029],{"trials":2049,"activeCount":96},[],{"trials":2051,"activeCount":96},[],{"trials":2053,"activeCount":96},[],{"trials":2055,"activeCount":96},[],{"intervention":2057,"totalTrials":92,"cells":2058},"Sulthiame",{"EARLY_PHASE1":2059,"PHASE1":2061,"PHASE2":2073,"PHASE3":2075,"PHASE4":2077,"NA":2079},{"trials":2060,"activeCount":96},[],{"trials":2062,"activeCount":96},[2063],{"nctId":2064,"briefTitle":2065,"status":479,"phases":2066,"primaryCompletion":2067,"completion":2068,"start":2069,"enrollment":20,"conditions":2070,"interventions":2072},"NCT03400189","Pharmacokinetics and Tolerability of Sulthiame",[85],"2018-05-22","2018-08-30","2018-02-12",[2071],"Epilepsy",[2057],{"trials":2074,"activeCount":96},[],{"trials":2076,"activeCount":96},[],{"trials":2078,"activeCount":96},[],{"trials":2080,"activeCount":96},[],{"intervention":2082,"totalTrials":92,"cells":2083},"Interferon beta-1a HSA-free biosimilar",{"EARLY_PHASE1":2084,"PHASE1":2086,"PHASE2":2098,"PHASE3":2100,"PHASE4":2102,"NA":2104},{"trials":2085,"activeCount":96},[],{"trials":2087,"activeCount":96},[2088],{"nctId":2089,"briefTitle":2090,"status":479,"phases":2091,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":11,"conditions":2094,"interventions":2095},"NCT02517788","Phase I BP Interferon (IFN) Beta-004",[85],"2006-07","2006-05",[2003],[2082,2096,2097],"Interferon beta-1a HSA+ biosimilar","Interferon beta-1a original",{"trials":2099,"activeCount":96},[],{"trials":2101,"activeCount":96},[],{"trials":2103,"activeCount":96},[],{"trials":2105,"activeCount":96},[],{"intervention":2096,"totalTrials":92,"cells":2107},{"EARLY_PHASE1":2108,"PHASE1":2110,"PHASE2":2116,"PHASE3":2118,"PHASE4":2120,"NA":2122},{"trials":2109,"activeCount":96},[],{"trials":2111,"activeCount":96},[2112],{"nctId":2089,"briefTitle":2090,"status":479,"phases":2113,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":11,"conditions":2114,"interventions":2115},[85],[2003],[2082,2096,2097],{"trials":2117,"activeCount":96},[],{"trials":2119,"activeCount":96},[],{"trials":2121,"activeCount":96},[],{"trials":2123,"activeCount":96},[],{"intervention":2097,"totalTrials":92,"cells":2125},{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2134,"PHASE3":2136,"PHASE4":2138,"NA":2140},{"trials":2127,"activeCount":96},[],{"trials":2129,"activeCount":96},[2130],{"nctId":2089,"briefTitle":2090,"status":479,"phases":2131,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":11,"conditions":2132,"interventions":2133},[85],[2003],[2082,2096,2097],{"trials":2135,"activeCount":96},[],{"trials":2137,"activeCount":96},[],{"trials":2139,"activeCount":96},[],{"trials":2141,"activeCount":96},[],{"intervention":2143,"totalTrials":92,"cells":2144},"Melan-A ELA + Montanide",{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2162,"PHASE3":2164,"PHASE4":2166,"NA":2168},{"trials":2146,"activeCount":96},[],{"trials":2148,"activeCount":96},[2149],{"nctId":2150,"briefTitle":2151,"status":479,"phases":2152,"primaryCompletion":2153,"completion":2153,"start":2154,"enrollment":2155,"conditions":2156,"interventions":2157},"NCT00112242","Immunotherapy of Stage III\u002FIV Melanoma Patients",[85],"2013-03","2004-02",39,[22],[2143,2158,2159,2160,2161],"Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide","Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG","Melan-A-EAA\u002FELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG","Melan-A-EAA\u002FELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2",{"trials":2163,"activeCount":96},[],{"trials":2165,"activeCount":96},[],{"trials":2167,"activeCount":96},[],{"trials":2169,"activeCount":96},[],{"intervention":2158,"totalTrials":92,"cells":2171},{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2180,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2173,"activeCount":96},[],{"trials":2175,"activeCount":96},[2176],{"nctId":2150,"briefTitle":2151,"status":479,"phases":2177,"primaryCompletion":2153,"completion":2153,"start":2154,"enrollment":2155,"conditions":2178,"interventions":2179},[85],[22],[2143,2158,2159,2160,2161],{"trials":2181,"activeCount":96},[],{"trials":2183,"activeCount":96},[],{"trials":2185,"activeCount":96},[],{"trials":2187,"activeCount":96},[],{"intervention":2159,"totalTrials":92,"cells":2189},{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2198,"PHASE3":2200,"PHASE4":2202,"NA":2204},{"trials":2191,"activeCount":96},[],{"trials":2193,"activeCount":96},[2194],{"nctId":2150,"briefTitle":2151,"status":479,"phases":2195,"primaryCompletion":2153,"completion":2153,"start":2154,"enrollment":2155,"conditions":2196,"interventions":2197},[85],[22],[2143,2158,2159,2160,2161],{"trials":2199,"activeCount":96},[],{"trials":2201,"activeCount":96},[],{"trials":2203,"activeCount":96},[],{"trials":2205,"activeCount":96},[],{"intervention":2160,"totalTrials":92,"cells":2207},{"EARLY_PHASE1":2208,"PHASE1":2210,"PHASE2":2216,"PHASE3":2218,"PHASE4":2220,"NA":2222},{"trials":2209,"activeCount":96},[],{"trials":2211,"activeCount":96},[2212],{"nctId":2150,"briefTitle":2151,"status":479,"phases":2213,"primaryCompletion":2153,"completion":2153,"start":2154,"enrollment":2155,"conditions":2214,"interventions":2215},[85],[22],[2143,2158,2159,2160,2161],{"trials":2217,"activeCount":96},[],{"trials":2219,"activeCount":96},[],{"trials":2221,"activeCount":96},[],{"trials":2223,"activeCount":96},[],{"intervention":2161,"totalTrials":92,"cells":2225},{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2234,"PHASE3":2236,"PHASE4":2238,"NA":2240},{"trials":2227,"activeCount":96},[],{"trials":2229,"activeCount":96},[2230],{"nctId":2150,"briefTitle":2151,"status":479,"phases":2231,"primaryCompletion":2153,"completion":2153,"start":2154,"enrollment":2155,"conditions":2232,"interventions":2233},[85],[22],[2143,2158,2159,2160,2161],{"trials":2235,"activeCount":96},[],{"trials":2237,"activeCount":96},[],{"trials":2239,"activeCount":96},[],{"trials":2241,"activeCount":96},[],{"intervention":490,"totalTrials":92,"cells":2243},{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2252,"PHASE3":2254,"PHASE4":2256,"NA":2258},{"trials":2245,"activeCount":96},[],{"trials":2247,"activeCount":96},[2248],{"nctId":477,"briefTitle":478,"status":479,"phases":2249,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":2250,"interventions":2251},[85],[486],[470,488,489,490],{"trials":2253,"activeCount":96},[],{"trials":2255,"activeCount":96},[],{"trials":2257,"activeCount":96},[],{"trials":2259,"activeCount":96},[],{"intervention":2261,"totalTrials":92,"cells":2262},"Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin\u002FCelecoxib",{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2275,"PHASE3":2277,"PHASE4":2279,"NA":2281},{"trials":2264,"activeCount":96},[],{"trials":2266,"activeCount":96},[2267],{"nctId":2268,"briefTitle":2269,"status":479,"phases":2270,"primaryCompletion":2271,"completion":2271,"start":2272,"enrollment":220,"conditions":2273,"interventions":2274},"NCT03728179","RACIN in Patients With Advanced TIL-negative Solid Tumors",[85],"2023-10-27","2019-01-16",[500],[2261],{"trials":2276,"activeCount":96},[],{"trials":2278,"activeCount":96},[],{"trials":2280,"activeCount":96},[],{"trials":2282,"activeCount":96},[],{"intervention":2284,"totalTrials":92,"cells":2285},"Autologous Platelet Rich Plasma",{"EARLY_PHASE1":2286,"PHASE1":2288,"PHASE2":2300,"PHASE3":2302,"PHASE4":2304,"NA":2306},{"trials":2287,"activeCount":96},[],{"trials":2289,"activeCount":96},[2290],{"nctId":2291,"briefTitle":2292,"status":479,"phases":2293,"primaryCompletion":2294,"start":2295,"enrollment":1675,"conditions":2296,"interventions":2298},"NCT00856934","Effect of Platelet Rich Plasma and Keratinocyte Suspensions on Wound Healing",[85],"2006-03","2005-06",[2297],"Skin Graft",[2284,2299],"Keratinocyte suspension",{"trials":2301,"activeCount":96},[],{"trials":2303,"activeCount":96},[],{"trials":2305,"activeCount":96},[],{"trials":2307,"activeCount":96},[],{"intervention":2299,"totalTrials":92,"cells":2309},{"EARLY_PHASE1":2310,"PHASE1":2312,"PHASE2":2318,"PHASE3":2320,"PHASE4":2322,"NA":2324},{"trials":2311,"activeCount":96},[],{"trials":2313,"activeCount":96},[2314],{"nctId":2291,"briefTitle":2292,"status":479,"phases":2315,"primaryCompletion":2294,"start":2295,"enrollment":1675,"conditions":2316,"interventions":2317},[85],[2297],[2284,2299],{"trials":2319,"activeCount":96},[],{"trials":2321,"activeCount":96},[],{"trials":2323,"activeCount":96},[],{"trials":2325,"activeCount":96},[],{"intervention":2327,"totalTrials":92,"cells":2328},"Buspirone",{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2344,"PHASE3":2346,"PHASE4":2348,"NA":2350},{"trials":2330,"activeCount":96},[],{"trials":2332,"activeCount":96},[2333],{"nctId":2334,"briefTitle":2335,"status":479,"phases":2336,"primaryCompletion":2337,"completion":2337,"start":417,"enrollment":29,"conditions":2338,"interventions":2341},"NCT04052776","Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES",[85],"2023-10-04",[2339,2340],"Spinal Cord Injuries","Drug Effect",[2327,2342,2343],"Levodopa-Carbidopa","Buspirone + Levodopa-Carbidopa",{"trials":2345,"activeCount":96},[],{"trials":2347,"activeCount":96},[],{"trials":2349,"activeCount":96},[],{"trials":2351,"activeCount":96},[],{"intervention":2342,"totalTrials":92,"cells":2353},{"EARLY_PHASE1":2354,"PHASE1":2356,"PHASE2":2362,"PHASE3":2364,"PHASE4":2366,"NA":2368},{"trials":2355,"activeCount":96},[],{"trials":2357,"activeCount":96},[2358],{"nctId":2334,"briefTitle":2335,"status":479,"phases":2359,"primaryCompletion":2337,"completion":2337,"start":417,"enrollment":29,"conditions":2360,"interventions":2361},[85],[2339,2340],[2327,2342,2343],{"trials":2363,"activeCount":96},[],{"trials":2365,"activeCount":96},[],{"trials":2367,"activeCount":96},[],{"trials":2369,"activeCount":96},[],{"intervention":2343,"totalTrials":92,"cells":2371},{"EARLY_PHASE1":2372,"PHASE1":2374,"PHASE2":2380,"PHASE3":2382,"PHASE4":2384,"NA":2386},{"trials":2373,"activeCount":96},[],{"trials":2375,"activeCount":96},[2376],{"nctId":2334,"briefTitle":2335,"status":479,"phases":2377,"primaryCompletion":2337,"completion":2337,"start":417,"enrollment":29,"conditions":2378,"interventions":2379},[85],[2339,2340],[2327,2342,2343],{"trials":2381,"activeCount":96},[],{"trials":2383,"activeCount":96},[],{"trials":2385,"activeCount":96},[],{"trials":2387,"activeCount":96},[],{"intervention":2389,"totalTrials":92,"cells":2390},"group 1",{"EARLY_PHASE1":2391,"PHASE1":2393,"PHASE2":2408,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2392,"activeCount":96},[],{"trials":2394,"activeCount":96},[2395],{"nctId":2396,"briefTitle":2397,"status":479,"phases":2398,"primaryCompletion":2399,"completion":2400,"start":2401,"enrollment":2402,"conditions":2403,"interventions":2404},"NCT00112229","Immunotherapy of HLA-A2 Positive Stage III\u002FIV Melanoma Patients",[85],"2011-08","2012-06","2003-04",29,[22],[2389,2405,2406,2407],"group 2","group 3","group 4",{"trials":2409,"activeCount":96},[],{"trials":2411,"activeCount":96},[],{"trials":2413,"activeCount":96},[],{"trials":2415,"activeCount":96},[],{"intervention":2405,"totalTrials":92,"cells":2417},{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2426,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2419,"activeCount":96},[],{"trials":2421,"activeCount":96},[2422],{"nctId":2396,"briefTitle":2397,"status":479,"phases":2423,"primaryCompletion":2399,"completion":2400,"start":2401,"enrollment":2402,"conditions":2424,"interventions":2425},[85],[22],[2389,2405,2406,2407],{"trials":2427,"activeCount":96},[],{"trials":2429,"activeCount":96},[],{"trials":2431,"activeCount":96},[],{"trials":2433,"activeCount":96},[],{"intervention":2406,"totalTrials":92,"cells":2435},{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2444,"PHASE3":2446,"PHASE4":2448,"NA":2450},{"trials":2437,"activeCount":96},[],{"trials":2439,"activeCount":96},[2440],{"nctId":2396,"briefTitle":2397,"status":479,"phases":2441,"primaryCompletion":2399,"completion":2400,"start":2401,"enrollment":2402,"conditions":2442,"interventions":2443},[85],[22],[2389,2405,2406,2407],{"trials":2445,"activeCount":96},[],{"trials":2447,"activeCount":96},[],{"trials":2449,"activeCount":96},[],{"trials":2451,"activeCount":96},[],{"intervention":2407,"totalTrials":92,"cells":2453},{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2462,"PHASE3":2464,"PHASE4":2466,"NA":2468},{"trials":2455,"activeCount":96},[],{"trials":2457,"activeCount":96},[2458],{"nctId":2396,"briefTitle":2397,"status":479,"phases":2459,"primaryCompletion":2399,"completion":2400,"start":2401,"enrollment":2402,"conditions":2460,"interventions":2461},[85],[22],[2389,2405,2406,2407],{"trials":2463,"activeCount":96},[],{"trials":2465,"activeCount":96},[],{"trials":2467,"activeCount":96},[],{"trials":2469,"activeCount":96},[],{"intervention":2471,"totalTrials":92,"cells":2472},"Melan-A analog peptide",{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2488,"PHASE3":2490,"PHASE4":2492,"NA":2494},{"trials":2474,"activeCount":96},[],{"trials":2476,"activeCount":96},[2477],{"nctId":2478,"briefTitle":2479,"status":479,"phases":2480,"primaryCompletion":189,"completion":189,"start":2481,"enrollment":581,"conditions":2482,"interventions":2483},"NCT00112216","Immunotherapy of Melanoma Patients",[85],"1999-05",[22],[2471,2484,2485,2486,2487],"FluMa peptide","Mage-A10 peptide","SB AS-2 adjuvant","Montanide adjuvant",{"trials":2489,"activeCount":96},[],{"trials":2491,"activeCount":96},[],{"trials":2493,"activeCount":96},[],{"trials":2495,"activeCount":96},[],{"intervention":2484,"totalTrials":92,"cells":2497},{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2506,"PHASE3":2508,"PHASE4":2510,"NA":2512},{"trials":2499,"activeCount":96},[],{"trials":2501,"activeCount":96},[2502],{"nctId":2478,"briefTitle":2479,"status":479,"phases":2503,"primaryCompletion":189,"completion":189,"start":2481,"enrollment":581,"conditions":2504,"interventions":2505},[85],[22],[2471,2484,2485,2486,2487],{"trials":2507,"activeCount":96},[],{"trials":2509,"activeCount":96},[],{"trials":2511,"activeCount":96},[],{"trials":2513,"activeCount":96},[],{"intervention":2485,"totalTrials":92,"cells":2515},{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2524,"PHASE3":2526,"PHASE4":2528,"NA":2530},{"trials":2517,"activeCount":96},[],{"trials":2519,"activeCount":96},[2520],{"nctId":2478,"briefTitle":2479,"status":479,"phases":2521,"primaryCompletion":189,"completion":189,"start":2481,"enrollment":581,"conditions":2522,"interventions":2523},[85],[22],[2471,2484,2485,2486,2487],{"trials":2525,"activeCount":96},[],{"trials":2527,"activeCount":96},[],{"trials":2529,"activeCount":96},[],{"trials":2531,"activeCount":96},[],{"intervention":2486,"totalTrials":92,"cells":2533},{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2542,"PHASE3":2544,"PHASE4":2546,"NA":2548},{"trials":2535,"activeCount":96},[],{"trials":2537,"activeCount":96},[2538],{"nctId":2478,"briefTitle":2479,"status":479,"phases":2539,"primaryCompletion":189,"completion":189,"start":2481,"enrollment":581,"conditions":2540,"interventions":2541},[85],[22],[2471,2484,2485,2486,2487],{"trials":2543,"activeCount":96},[],{"trials":2545,"activeCount":96},[],{"trials":2547,"activeCount":96},[],{"trials":2549,"activeCount":96},[],{"intervention":2487,"totalTrials":92,"cells":2551},{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2560,"PHASE3":2562,"PHASE4":2564,"NA":2566},{"trials":2553,"activeCount":96},[],{"trials":2555,"activeCount":96},[2556],{"nctId":2478,"briefTitle":2479,"status":479,"phases":2557,"primaryCompletion":189,"completion":189,"start":2481,"enrollment":581,"conditions":2558,"interventions":2559},[85],[22],[2471,2484,2485,2486,2487],{"trials":2561,"activeCount":96},[],{"trials":2563,"activeCount":96},[],{"trials":2565,"activeCount":96},[],{"trials":2567,"activeCount":96},[],{"intervention":2569,"totalTrials":92,"cells":2570},"mannitol-enhanced aminoglycoside",{"EARLY_PHASE1":2571,"PHASE1":2587,"PHASE2":2589,"PHASE3":2591,"PHASE4":2593,"NA":2595},{"trials":2572,"activeCount":96},[2573],{"nctId":2574,"briefTitle":2575,"status":187,"phases":2576,"primaryCompletion":2577,"completion":2578,"start":2579,"enrollment":2580,"conditions":2581,"interventions":2584},"NCT05761405","Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis",[84],"2025-10-15","2026-04-15","2024-01-16",90,[2582,2583],"Urinary Tract Infections","Urological System Complication of Procedure",[2569,2585,2586],"Ceftriaxon","Amikacin",{"trials":2588,"activeCount":96},[],{"trials":2590,"activeCount":96},[],{"trials":2592,"activeCount":96},[],{"trials":2594,"activeCount":96},[],{"trials":2596,"activeCount":96},[],{"intervention":2585,"totalTrials":92,"cells":2598},{"EARLY_PHASE1":2599,"PHASE1":2605,"PHASE2":2607,"PHASE3":2609,"PHASE4":2611,"NA":2613},{"trials":2600,"activeCount":96},[2601],{"nctId":2574,"briefTitle":2575,"status":187,"phases":2602,"primaryCompletion":2577,"completion":2578,"start":2579,"enrollment":2580,"conditions":2603,"interventions":2604},[84],[2582,2583],[2569,2585,2586],{"trials":2606,"activeCount":96},[],{"trials":2608,"activeCount":96},[],{"trials":2610,"activeCount":96},[],{"trials":2612,"activeCount":96},[],{"trials":2614,"activeCount":96},[],{"intervention":2586,"totalTrials":92,"cells":2616},{"EARLY_PHASE1":2617,"PHASE1":2623,"PHASE2":2625,"PHASE3":2627,"PHASE4":2629,"NA":2631},{"trials":2618,"activeCount":96},[2619],{"nctId":2574,"briefTitle":2575,"status":187,"phases":2620,"primaryCompletion":2577,"completion":2578,"start":2579,"enrollment":2580,"conditions":2621,"interventions":2622},[84],[2582,2583],[2569,2585,2586],{"trials":2624,"activeCount":96},[],{"trials":2626,"activeCount":96},[],{"trials":2628,"activeCount":96},[],{"trials":2630,"activeCount":96},[],{"trials":2632,"activeCount":96},[],{"intervention":2634,"totalTrials":92,"cells":2635},"Fentanyl",{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2640,"PHASE3":2642,"PHASE4":2644,"NA":2646},{"trials":2637,"activeCount":96},[],{"trials":2639,"activeCount":96},[],{"trials":2641,"activeCount":96},[],{"trials":2643,"activeCount":96},[],{"trials":2645,"activeCount":96},[],{"trials":2647,"activeCount":96},[2648],{"nctId":2649,"briefTitle":2650,"status":479,"phases":2651,"primaryCompletion":2652,"completion":2652,"start":922,"enrollment":2653,"conditions":2654,"interventions":2656},"NCT02531165","Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention",[89],"2018-02-06",38,[2655],"Acute Myocardial Infarction",[2634,2657,2658,2659,2660],"Morphine","Ticagrelor","Aspirin","Unfractioned Heparin",{"intervention":2657,"totalTrials":92,"cells":2662},{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2671,"NA":2673},{"trials":2664,"activeCount":96},[],{"trials":2666,"activeCount":96},[],{"trials":2668,"activeCount":96},[],{"trials":2670,"activeCount":96},[],{"trials":2672,"activeCount":96},[],{"trials":2674,"activeCount":96},[2675],{"nctId":2649,"briefTitle":2650,"status":479,"phases":2676,"primaryCompletion":2652,"completion":2652,"start":922,"enrollment":2653,"conditions":2677,"interventions":2678},[89],[2655],[2634,2657,2658,2659,2660],{"intervention":2658,"totalTrials":92,"cells":2680},{"EARLY_PHASE1":2681,"PHASE1":2683,"PHASE2":2685,"PHASE3":2687,"PHASE4":2689,"NA":2691},{"trials":2682,"activeCount":96},[],{"trials":2684,"activeCount":96},[],{"trials":2686,"activeCount":96},[],{"trials":2688,"activeCount":96},[],{"trials":2690,"activeCount":96},[],{"trials":2692,"activeCount":96},[2693],{"nctId":2649,"briefTitle":2650,"status":479,"phases":2694,"primaryCompletion":2652,"completion":2652,"start":922,"enrollment":2653,"conditions":2695,"interventions":2696},[89],[2655],[2634,2657,2658,2659,2660],{"intervention":2659,"totalTrials":92,"cells":2698},{"EARLY_PHASE1":2699,"PHASE1":2701,"PHASE2":2703,"PHASE3":2705,"PHASE4":2707,"NA":2709},{"trials":2700,"activeCount":96},[],{"trials":2702,"activeCount":96},[],{"trials":2704,"activeCount":96},[],{"trials":2706,"activeCount":96},[],{"trials":2708,"activeCount":96},[],{"trials":2710,"activeCount":96},[2711],{"nctId":2649,"briefTitle":2650,"status":479,"phases":2712,"primaryCompletion":2652,"completion":2652,"start":922,"enrollment":2653,"conditions":2713,"interventions":2714},[89],[2655],[2634,2657,2658,2659,2660],{"intervention":2660,"totalTrials":92,"cells":2716},{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2721,"PHASE3":2723,"PHASE4":2725,"NA":2727},{"trials":2718,"activeCount":96},[],{"trials":2720,"activeCount":96},[],{"trials":2722,"activeCount":96},[],{"trials":2724,"activeCount":96},[],{"trials":2726,"activeCount":96},[],{"trials":2728,"activeCount":96},[2729],{"nctId":2649,"briefTitle":2650,"status":479,"phases":2730,"primaryCompletion":2652,"completion":2652,"start":922,"enrollment":2653,"conditions":2731,"interventions":2732},[89],[2655],[2634,2657,2658,2659,2660],{"intervention":2734,"totalTrials":92,"cells":2735},"Ropivacaine 0.5% Injectable Solution",{"EARLY_PHASE1":2736,"PHASE1":2738,"PHASE2":2740,"PHASE3":2742,"PHASE4":2744,"NA":2746},{"trials":2737,"activeCount":96},[],{"trials":2739,"activeCount":96},[],{"trials":2741,"activeCount":96},[],{"trials":2743,"activeCount":96},[],{"trials":2745,"activeCount":96},[],{"trials":2747,"activeCount":96},[2748],{"nctId":2749,"briefTitle":2750,"status":479,"phases":2751,"primaryCompletion":2752,"completion":2753,"start":2754,"enrollment":693,"conditions":2755,"interventions":2757},"NCT03698006","Selective Tibial Nerve Block vs Local Infiltration Analgesia After Prothetic Knee Surgery",[89],"2022-01-31","2022-06-30","2021-02-12",[15,2756],"Knee Osteoarthritis",[2734,2758],"Ropivacaine 0.2% Injectable Solution",{"intervention":2758,"totalTrials":92,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2767,"PHASE4":2769,"NA":2771},{"trials":2762,"activeCount":96},[],{"trials":2764,"activeCount":96},[],{"trials":2766,"activeCount":96},[],{"trials":2768,"activeCount":96},[],{"trials":2770,"activeCount":96},[],{"trials":2772,"activeCount":96},[2773],{"nctId":2749,"briefTitle":2750,"status":479,"phases":2774,"primaryCompletion":2752,"completion":2753,"start":2754,"enrollment":693,"conditions":2775,"interventions":2776},[89],[15,2756],[2734,2758],{"intervention":2778,"totalTrials":92,"cells":2779},"Cinacalcet 60 MG",{"EARLY_PHASE1":2780,"PHASE1":2782,"PHASE2":2784,"PHASE3":2786,"PHASE4":2788,"NA":2790},{"trials":2781,"activeCount":96},[],{"trials":2783,"activeCount":96},[],{"trials":2785,"activeCount":96},[],{"trials":2787,"activeCount":96},[],{"trials":2789,"activeCount":96},[],{"trials":2791,"activeCount":96},[2792],{"nctId":2793,"briefTitle":2794,"status":479,"phases":2795,"primaryCompletion":2400,"completion":2796,"start":2797,"enrollment":484,"conditions":2798,"interventions":2800},"NCT01519037","Interaction Between a Calcimimetic Agent and the Renin Angiotensine Aldosterone System",[89],"2014-06","2012-01",[2799],"Relationship Between Calcimimetic and the RAAS",[2778],{"intervention":2802,"totalTrials":92,"cells":2803},"Co-administration of darunavir with a cardiovascular drug",{"EARLY_PHASE1":2804,"PHASE1":2806,"PHASE2":2808,"PHASE3":2810,"PHASE4":2812,"NA":2814},{"trials":2805,"activeCount":96},[],{"trials":2807,"activeCount":96},[],{"trials":2809,"activeCount":96},[],{"trials":2811,"activeCount":96},[],{"trials":2813,"activeCount":96},[],{"trials":2815,"activeCount":96},[2816],{"nctId":2817,"briefTitle":2818,"status":479,"phases":2819,"primaryCompletion":2820,"completion":2820,"start":2821,"enrollment":2822,"conditions":2823,"interventions":2827},"NCT03515772","Drug-drug Interactions Between Antiretroviral Drugs and Cardiovascular Drugs in Elderly Patients",[],"2019-08-29","2018-04-23",21,[2824,2825,2826],"HIV Infections","Drug Interactions","Cardiovascular Diseases",[2802],{"intervention":2829,"totalTrials":92,"cells":2830},"intra-articular infiltration",{"EARLY_PHASE1":2831,"PHASE1":2833,"PHASE2":2835,"PHASE3":2837,"PHASE4":2839,"NA":2841},{"trials":2832,"activeCount":96},[],{"trials":2834,"activeCount":96},[],{"trials":2836,"activeCount":96},[],{"trials":2838,"activeCount":96},[],{"trials":2840,"activeCount":96},[],{"trials":2842,"activeCount":96},[2843],{"nctId":2844,"briefTitle":2845,"status":479,"phases":2846,"primaryCompletion":2847,"completion":1753,"start":2848,"enrollment":2849,"conditions":2850,"interventions":2853},"NCT01420497","Systemic Effects of Epidural Methylprednisolone Injection on Glucose Tolerance in Diabetic Patients",[89],"2008-09","2008-08",25,[2851,2852],"Diabetes","Healthy",[2829,2854],"epidural infiltration",{"intervention":2854,"totalTrials":92,"cells":2856},{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2863,"PHASE4":2865,"NA":2867},{"trials":2858,"activeCount":96},[],{"trials":2860,"activeCount":96},[],{"trials":2862,"activeCount":96},[],{"trials":2864,"activeCount":96},[],{"trials":2866,"activeCount":96},[],{"trials":2868,"activeCount":96},[2869],{"nctId":2844,"briefTitle":2845,"status":479,"phases":2870,"primaryCompletion":2847,"completion":1753,"start":2848,"enrollment":2849,"conditions":2871,"interventions":2872},[89],[2851,2852],[2829,2854],{"intervention":2874,"totalTrials":92,"cells":2875},"Ropivacaine",{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2882,"PHASE4":2884,"NA":2886},{"trials":2877,"activeCount":96},[],{"trials":2879,"activeCount":96},[],{"trials":2881,"activeCount":96},[],{"trials":2883,"activeCount":96},[],{"trials":2885,"activeCount":96},[],{"trials":2887,"activeCount":96},[2888],{"nctId":2889,"briefTitle":2890,"status":479,"phases":2891,"primaryCompletion":2892,"completion":2892,"start":735,"enrollment":693,"conditions":2893,"interventions":2896},"NCT03680716","Combined Saphenous Nerve and IPACK Blocks Versus Infiltration Analgesia After Anterior Cruciate Ligament Reconstruction",[89],"2020-10-01",[15,2894,2895],"Anterior Cruciate Ligament Injury","Anterior Cruciate Ligament Rupture",[2874,2874],{"intervention":2898,"totalTrials":92,"cells":2899},"Furosemide stress test",{"EARLY_PHASE1":2900,"PHASE1":2902,"PHASE2":2904,"PHASE3":2906,"PHASE4":2908,"NA":2910},{"trials":2901,"activeCount":96},[],{"trials":2903,"activeCount":96},[],{"trials":2905,"activeCount":96},[],{"trials":2907,"activeCount":96},[],{"trials":2909,"activeCount":96},[],{"trials":2911,"activeCount":96},[2912],{"nctId":2913,"briefTitle":2914,"status":479,"phases":2915,"primaryCompletion":2916,"completion":2917,"start":2918,"enrollment":2919,"conditions":2920,"interventions":2922},"NCT05612490","Furosemide Stress Test to Predict Successful Liberation From RRT",[],"2025-06-04","2025-07-09","2023-01-17",52,[2921],"Acute Kidney Injury",[2898],{"intervention":2924,"totalTrials":92,"cells":2925},"Autologous blood transfusion",{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2930,"PHASE3":2932,"PHASE4":2934,"NA":2936},{"trials":2927,"activeCount":96},[],{"trials":2929,"activeCount":96},[],{"trials":2931,"activeCount":96},[],{"trials":2933,"activeCount":96},[],{"trials":2935,"activeCount":96},[],{"trials":2937,"activeCount":96},[2938],{"nctId":2939,"briefTitle":2940,"status":479,"phases":2941,"primaryCompletion":2942,"completion":2943,"start":835,"enrollment":375,"conditions":2944,"interventions":2946},"NCT02423135","Detection of Autologous DEHP (DiEthylHexyl Phthalate)-Free Blood Transfusion in Anti-doping",[89],"2015-01","2015-02",[2945],"Transfusion Reaction",[2924],{"intervention":2948,"totalTrials":92,"cells":2949},"metformin",{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2954,"PHASE3":2956,"PHASE4":2958,"NA":2960},{"trials":2951,"activeCount":96},[],{"trials":2953,"activeCount":96},[],{"trials":2955,"activeCount":96},[],{"trials":2957,"activeCount":96},[],{"trials":2959,"activeCount":96},[],{"trials":2961,"activeCount":96},[2962],{"nctId":2963,"briefTitle":2964,"status":479,"phases":2965,"primaryCompletion":692,"start":2966,"enrollment":2967,"conditions":2968,"interventions":2972},"NCT02793505","Safety of Metformin in Pregnancy",[],"2014-01",950,[2969,2970,2971],"Pregnancy","Pregestational Diabetes","Polycystic Ovary Syndrom",[2948,2973],"any drug not known as a major teratogen or major fetotoxicant",{"intervention":2973,"totalTrials":92,"cells":2975},{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2980,"PHASE3":2982,"PHASE4":2984,"NA":2986},{"trials":2977,"activeCount":96},[],{"trials":2979,"activeCount":96},[],{"trials":2981,"activeCount":96},[],{"trials":2983,"activeCount":96},[],{"trials":2985,"activeCount":96},[],{"trials":2987,"activeCount":96},[2988],{"nctId":2963,"briefTitle":2964,"status":479,"phases":2989,"primaryCompletion":692,"start":2966,"enrollment":2967,"conditions":2990,"interventions":2991},[],[2969,2970,2971],[2948,2973]]